Breast Biopsy Market by Product (Needles, Tables, Assay Kit), by Type (Needle Biopsy (CNB, FNAB, VAB), Liquid Biopsy (CTC, ctDNA)), Guidance (Image-Guided (Mammography, Ultrasound, MRI), Liquid Biopsy (NGS, PCR, Microarray-based)) - Global Forecasts to 2025
Updated on : February 21, 2023
The global breast biopsy market in terms of revenue was estimated to be worth $725 million in 2020 and is poised to reach $1,094 million by 2025, growing at a CAGR of 8.6% from 2020 to 2025. New product approvals and launches coupled with growing inclination towards minimally invasive and image-guided needle biopsies (such as vacuum-assisted biopsy and core needle biopsy) are responsible for the significant growth of the market during the review period.
To know about the assumptions considered for the study, Request for Free Sample Report
Breast Biopsy Market Dynamics
Drivers: Growing incidence of breast cancer
Breast cancer is among the most common diseases affecting women in developed as well as developing countries. According to the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women across the globe.
- In the US, one in eight women develops invasive breast cancer for her lifetime. According to the American Cancer Society and the National Cancer Institute, in 2018, over 265,000 new cases of invasive breast cancer were diagnosed among women in the US, with 63,960 new cases of non-invasive (in situ) breast cancer (Source: Breastcancer.org).
- In Canada, as many as 26,300 women were diagnosed with breast cancer in 2017, representing 25% new cancer cases (Source: Canadian Cancer Society), i.e., 72 Canadian women are diagnosed with breast cancer every day.
- More than 70,000 newly diagnosed cases of breast cancer are reported in Germany every year (Source: Roche).
The increasing number of breast cancer cases has forced governments across the globe to raise awareness regarding the importance of early detection of breast cancer, which is expected to drive the market growth.
Restraints: Risk of infections associated with the use of biopsy needles
Biopsy needle procedures, such as core needle and fine needle procedures, assist radiologists and surgeons in examining abnormalities at a particular site. However, patients can contract infections during these procedures as they involve cuts and incisions for removing tissue samples. In several cases, biopsy needles are reused, which further increases the risk of infection during these procedures. While healthcare authorities as well as product manufacturers do no recommend the reuse of some needles, the practice is still prevalent, especially in developing countries.
Thus, to avoid the risk of infections from these procedures, healthcare providers as well as patients may opt for alternative diagnostic procedures for target conditions.
Opportunities: Emergence of liquid biopsy and promising clinical trials
Liquid biopsy is a blood test that assists physicians to identify cancer cells (circulating tumor cells) or DNA fragments of tumors in blood. This technique eliminates the need to carry out surgical and needle biopsies and helps physicians to identify the occurrence of cancer in the early stages. It also captures the entire genetic complexity of tumors and helps limit the chances of cancer cells spreading to other parts of the body. Currently, various players are conducting clinical trials to prove the effectiveness and efficiency of liquid biopsy in oncology; the promising results are expected to create new opportunities for players operating in the market.
Challenges: Underdeveloped healthcare infrastructure and the dearth of resources in developing countries
With the growing awareness about different types of cancers, the demand for biopsy procedures is expected to increase in the coming years. However, there is a shortage of skilled surgeons to perform minimally invasive biopsy procedures. For instance, a shortage of more than 2,300 medical oncologists is expected in the US by 2025 (Source: Journal of Global Oncology). The effect of such shortages will be more pronounced in developing and underdeveloped regions.
The underdeveloped healthcare infrastructure is another major factor limiting the growth of the breast biopsy market in developing countries. For instance, in India, guidelines for population-based screening programs for breast and cervical cancer have been established based on visual inspection tests. Despite these guidelines, the screening coverage in the country is very low.
To know about the assumptions considered for the study, download the pdf brochure
By product, the biopsy needle segment held major share of the breast biopsy market
The biopsy needles segment is expected to hold major hare of the market owing to the rising adoption of image guided procedures in developed as well as developing countries, and the introduction of technologically advanced and novel designs. For instance, the tri-axial needle, which is composed of a pincer needle on the outermost side, an outer cutting needle, and a sharp stylet on the inner side. The needle design allows healthcare professionals to cut through tissue without compressing it. Due to its specific design, the needle shows good visibility under ultrasound and CT, which are commonly used for biopsy guidance.
By type, liquid biopsy segment is anticipated to register highest growth
Liquid biopsy has emerged as a revolutionary technique that is providing new dimensions to the field of oncology diagnostics. The significant growth of the segment is attributed to the growing adoption of novel NGS-based assays and droplet digital PCR technology to perform liquid biopsies in most developed countries. Companies operating in the segment are focusing more on research and developmental activities to deliver novel products in the market. Thus, ongoing clinical trials and a promising product pipeline will further drive market growth.
Early diagnosis is the key application of the breast biopsy procedures
A biopsy is a confirmatory test that enables early diagnosis of a cancer/tumor, resulting in speedy recovery, increased lifespan, and reduced morbidity and mortality. Health professionals recommend breast biopsy for early breast cancer detection. Various government and private organizations, companies operating in the market, and hospitals are undertaking novel initiatives to raise public awareness about breast cancer and the clinical advantages of its early diagnosis through screening programs. These initiatives to increase awareness about early detection and diagnosis of breast cancer are consequently expected to fuel the demand for breast biopsy systems, further driving market growth.
In terms of guidance, the image-guided biopsy accounted for the largest share of the breast biopsy market
The role of breast imaging modalities has evolved from cancer detection and screening to include cancer diagnosis and management. Image guided breast biopsy procedures are minimally invasive and as accurate as open surgical biopsies. They are a safe approach for diagnosis in patients with breast microcalcifications. Thus, rising adoption of image- guided needle biopsy procedures are driving growth of the segment.
Asia Pacific market to register highest growth for the breast biopsy market
The healthcare infrastructure in emerging economies such as China, India, and South Korea is evolving at a rapid pace, leading to major investments in advanced systems (including liquid breast biopsy, and vacuum-assisted biopsy instruments, among others) by hospitals and breast care centers. This factor is driving the growth of Asia pacific breast biopsy market. Moreover, rising prevalence of breast cancer, growing number of awareness programs for the early detection of breast cancer, and the high government spending on breast cancer research studies are the other major factors driving the growth of the global market in Asia Pacific.
Key players of the global market are Hologic, Inc. (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), QIAGEN (Netherlands), and Illumina, Inc. (US) are the top five players in the global market. Other prominent players operating in this market include Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), and Thermo Fisher Scientific, Inc. (US), among others.
Hologic, Inc. holds the leading position in the global market, owing to its robust portfolio of breast biopsy products and related accessories. The company has expanded its product portfolio through insight-driven innovation and product launches to establish its position in the market. For instance, during the last three years, Hologic launched the Brevera Breast Biopsy System with CorLumina Imaging Technology in the US and Europe, which are the leading markets for breast biopsy. Hologic is expected to witness sustainable growth during the forecast period with its broad and technologically advanced product portfolio, wide geographic reach, and high product promotional activities.
Breast Biopsy Market Report Scope:
|
Report Metric |
Details |
|
Market Size Available for Years |
2018–2025 |
|
Base Year Considered |
2019 |
|
Forecast Period |
2020–205 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Technology, End-user, and Region |
|
Geographies Covered |
North America (US & Canada), Europe (Germany, France, UK, Italy, Spain, and RoE), APAC (Japan, China, India, Australia, South Korea, and RoAPAC), Latin America (Brazil, Mexico, and, RoLA), and Middle East & Africa |
|
Companies Covered |
Hologic, Inc. (US), Becton, Dickinson and Company (US), Danaher Corporation (US), Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), QIAGEN (Netherlands), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), Thermo Fisher Scientific, Inc. (US), Cardiff Oncology, Inc. (US), Myriad Genetics, Inc. (US), Illumina, Inc. (US), and Fluxion Biosciences Inc (US). Major 20 players covered. |
This research report categorizes the breast biopsy market into following segments & sub-segments:
By Product
- Biopsy Needles
- Guidance Systems
- Biopsy Tables
- Localization Wires
- Assay Kits
- Liquid Biopsy Instruments
- Others
By Type
- Needle Breast Biopsy
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy (FNAB)
- Vacuum-assisted Biopsy (VAB)
- Open Surgical Breast Biopsy
- Excisional
- Incisional
- Liquid Breast Biopsy
- Circulating Tumor Cells
- Circulating Tumor DNA (CtDNA)
- Other Biomarkers
By Guidance
- Image-Guided Biopsy
- Mammography-guided Stereotactic Biopsy
- Ultrasound-guided Biopsy
- MRI-guided Biopsy
- Other Guidance Techniques
- Liquid Biopsy
- NGS-based Biopsy
- PCR-based Biopsy
- Microarray-based Biopsy
By Application
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- RoE
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- RoAPAC
-
Latin America
- Brazil
- Mexico
- RoLA
- Middle East & Africa
Recent Developments
- In 2018, Hologic received the European CE mark approval for its Brevera Breast Biopsy System with CorLumina Imaging Technology. This system is designed to increase biopsy accuracy with real-time imaging, improve patient satisfaction, and streamline workflow in the biopsy suite.
- In 2017, Hologic announced the launch of its Brevera Breast Biopsy System with CorLumina Imaging Technology for commercial availability in the US. This system is designed to increase biopsy accuracy with real-time imaging, improve patient experience, and streamline the biopsy process from start to finish.
Frequently Asked Questions (FAQs):
What is the size of Breast Biopsy Market ?
The global breast biopsy market is projected to reach USD 1,094 million by 2025, growing at a CAGR of 8.6%.
What are the major growth factors of Breast Biopsy Market ?
New product approvals and launches coupled with growing inclination towards minimally invasive and image-guided needle biopsies (such as vacuum-assisted biopsy and core needle biopsy) are responsible for the significant growth of the market during the review period.
Who all are the prominent players of Breast Biopsy Market ?
The leading players in the Breast Biopsy Market include Hologic, Inc. (US), Danaher Corporation (US), and Becton, Dickinson and Company (US), QIAGEN (Netherlands), and Illumina, Inc. (US) are the top five players in the global breast biopsy market. Other prominent players operating in this market include Merit Medical Systems (US), Medtronic (Ireland), IZI Medical Products (US), Argon Medical (US), STERYLAB S.r.l. (Italy), Scion Medical Technologies, LLC (China), Biocept Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Menarini Silicon Biosystems, Spa (Italy), Exact Sciences Corporation (US), and Thermo Fisher Scientific, Inc. (US), among others. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 23)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 28)
2.1 RESEARCH DATA
FIGURE 1 GLOBAL BREAST BIOPSY MARKET: RESEARCH METHODOLOGY STEPS
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.1.2.2 Key data from primary sources
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 VENDOR REVENUE-BASED MARKET ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.2 END USER-BASED MARKET SIZE ESTIMATION
FIGURE 6 GLOBAL MARKET: END USER BASED ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 38)
FIGURE 8 BREAST BIOPSY MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
FIGURE 9 GLOBAL MARKET SHARE, BY TYPE, 2020 VS. 2025
FIGURE 10 GLOBAL MARKET, BY GUIDANCE, 2020 VS. 2025 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY APPLICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 42)
4.1 BREAST BIOPSY: MARKET OVERVIEW
FIGURE 13 INCREASING PREVALENCE OF BREAST CANCER DRIVING GROWTH OF GLOBAL MARKET ACROSS THE GLOBE
4.2 GEOGRAPHIC ANALYSIS: GLOBAL MARKET, BY PRODUCT AND REGION
FIGURE 14 ASSAY KITS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2025
4.3 GEOGRAPHIC ANALYSIS: NEEDLE BREAST-BIOPSY MARKET, BY TYPE AND REGION
FIGURE 15 CORE NEEDLE BIOPSY SEGMENT DOMINATED THE ASIA PACIFIC NEEDLE BREAST-BIOPSY MARKET IN 2020
4.4 LIQUID BREAST-BIOPSY MARKET, BY GUIDANCE
FIGURE 16 NGS-BASED BIOPSY TO REGISTER SIGNIFICANT GROWTH IN THE GLOBAL LIQUID BIOPSY MARKET, BY GUIDANCE
4.5 GEOGRAPHIC ANALYSIS: GLOBAL MARKET, BY APPLICATION AND REGION
FIGURE 17 EARLY CANCER SCREENING IS KEY APPLICATION IN EUROPEAN MARKET; THERAPY SELECTION TO REGISTER SUBSTANTIAL GROWTH
4.6 GEOGRAPHIC SNAPSHOT OF THE GLOBAL MARKET
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 47)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 BREAST BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing incidence of breast cancer
FIGURE 20 NUMBER OF BREAST CANCER CASES IN 2018, BY KEY COUNTRIES
5.2.1.2 Increasing number of breast cancer screening programs
5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures
5.2.1.4 Growing awareness regarding early detection of breast cancer
5.2.1.5 Improved reimbursement scenario
TABLE 1 MEDICARE REIMBURSEMENT FOR BREAST BIOPSY
5.2.2 RESTRAINTS
5.2.2.1 Risk of infections associated with the use of biopsy needles
5.2.2.2 Stringent regulatory approval procedures
5.2.2.3 Product recalls
TABLE 2 FDA INITIATED PRODUCT RECALLS
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies offer high growth potential
5.2.3.2 Emergence of liquid biopsy and promising clinical trials
TABLE 3 LIQUID BIOPSY CLINICL TRIALS
5.2.3.3 Increasing public–private investments and funding
5.2.4 CHALLENGES
5.2.4.1 Underdeveloped healthcare infrastructure and dearth of resources in developing countries
5.3 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM: GLOBAL MARKET
5.5 TECHNOLOGY ANALYSIS
5.6 IMPACT OF COVID-19 ON GLOBAL MARKET
6 BREAST BIOPSY MARKET, BY PRODUCT (Page No. - 59)
6.1 INTRODUCTION
TABLE 4 GLOBAL MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 5 GLOBAL MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2 BIOPSY NEEDLES
6.2.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE REVENUE GROWTH
TABLE 6 BIOPSY NEEDLES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.2.2 BIOPSY NEEDLES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 7 BIOPSY NEEDLES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.2.3 BIOPSY NEEDLES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 8 BIOPSY NEEDLES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.2.4 BIOPSY NEEDLES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 9 BIOPSY NEEDLES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.3 GUIDANCE SYSTEMS
6.3.1 PROCEDURAL ADVANTAGES OF GUIDED BIOPSIES TO FUEL RAPID MARKET EXPANSION
TABLE 10 GUIDANCE SYSTEMS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.3.2 GUIDANCE SYSTEMS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 11 GUIDANCE SYSTEMS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.3.3 GUIDANCE SYSTEMS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 12 GUIDANCE SYSTEMS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.3.4 GUIDANCE SYSTEMS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 13 GUIDANCE SYSTEMS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.4 BIOPSY TABLES
6.4.1 INCREASINGLY USED TO PERFORM STEREOTACTIC BIOPSY PROCEDURES
TABLE 14 BIOPSY TABLES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.4.2 BIOPSY TABLES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 15 BIOPSY TABLES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.4.3 BIOPSY TABLES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 16 BIOPSY TABLES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.4.4 BIOPSY TABLES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 17 BIOPSY TABLES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.5 ASSAY KITS
6.5.1 PRODUCT APPROVAL AND LAUNCHES DRIVING SEGMENT GROWTH
TABLE 18 ASSAY KITS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.5.2 ASSAY KITS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 19 ASSAY KITS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.5.3 ASSAY KITS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 20 ASSAY KITS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.5.4 ASSAY KITS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 21 ASSAY KITS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.6 LIQUID BIOPSY INSTRUMENTS
6.6.1 ONGOING RESEARCH AND CLINICAL TRIALS EXPECTED TO DELIVER NOVEL SOLUTIONS IN THE MARKET
TABLE 22 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.6.2 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 23 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.6.3 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 24 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.6.4 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 25 LIQUID BIOPSY INSTRUMENTS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.7 LOCALIZATION WIRES
6.7.1 MOST COMMONLY USED TO LOCATE BREAST ABNORMALITIES AND LUMPS
TABLE 26 LOCALIZATION WIRES MARKET, BY REGION, 2018–2025 (USD MILLION)
6.7.2 LOCALIZATION WIRES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 27 LOCALIZATION WIRES MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.7.3 LOCALIZATION WIRES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 28 LOCALIZATION WIRES MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.7.4 LOCALIZATION WIRES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 29 LOCALIZATION WIRES MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
6.8 OTHER PRODUCTS
6.8.1 RISING PATIENT POPULATION AND INCREASING ADOPTION OF BIOPSY PROCEDURES TO SUPPORT SEGMENT GROWTH
TABLE 30 OTHER PRODUCTS MARKET, BY REGION, 2018–2025 (USD MILLION)
6.8.2 OTHER PRODUCTS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
TABLE 31 OTHER PRODUCTS MARKET SPLIT, BY TYPE, 2018–2025 (USD MILLION)
6.8.3 OTHER PRODUCTS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 32 OTHER PRODUCTS MARKET SPLIT, BY GUIDANCE, 2018–2025 (USD MILLION)
6.8.4 OTHER PRODUCTS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 33 OTHER PRODUCTS MARKET SPLIT, BY APPLICATION, 2018–2025 (USD MILLION)
7 BREAST BIOPSY MARKET, BY TYPE (Page No. - 76)
7.1 INTRODUCTION
TABLE 34 GLOBAL MARKET, BY TYPE, 2018–2025 (USD MILLION)
7.2 NEEDLE BREAST BIOPSY
TABLE 35 GLOBAL MARKET FOR NEEDLE BREAST BIOPSY, BY TYPE, 2018–2025 (USD MILLION)
7.2.1 CORE NEEDLE BIOPSY
7.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth
TABLE 36 GLOBAL MARKET FOR CORE NEEDLE BIOPSY, BY REGION, 2018–2025 (USD MILLION)
7.2.2 VACUUM-ASSISTED BIOPSY (VAB)
7.2.2.1 Technological advantages supporting growth of segment
TABLE 37 GLOBAL MARKET FOR VACUUM-ASSISTED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
7.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB)
7.2.3.1 Increasingly being replaced by core needle biopsy procedures
TABLE 38 GLOBAL MARKET FOR FINE NEEDLE ASPIRATION BIOPSY, BY REGION, 2018–2025 (USD MILLION)
7.3 OPEN SURGICAL BREAST BIOPSY
TABLE 39 GLOBAL MARKET FOR OPEN SURGICAL BREAST BIOPSY, BY TYPE, 2018–2025 (USD MILLION)
7.3.1 EXCISIONAL
7.3.1.1 Risk of post-operative complications hindering growth of segment
TABLE 40 GLOBAL MARKET FOR EXCISIONAL, BY REGION, 2018–2025 (USD MILLION)
7.3.2 INCISIONAL
7.3.2.1 Performed when size of tumor is quite large
TABLE 41 GLOBAL MARKET FOR INCISIONAL, BY REGION, 2018–2025 (USD MILLION)
7.4 LIQUID BREAST BIOPSY
TABLE 42 GLOBAL MARKET FOR LIQUID BREAST BIOPSY, BY TYPE, 2018–2025 (USD MILLION)
7.4.1 CIRCULATING TUMOR CELLS
7.4.1.1 Difficult to identify limited presence in blood sample
TABLE 43 GLOBAL MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2018–2025 (USD MILLION)
7.4.2 CIRCULATING TUMOR DNA (CTDNA)
7.4.2.1 Promising blood-based biomarker to monitor disease status
TABLE 44 GLOBAL MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2018–2025 (USD MILLION)
7.4.3 OTHER BIOMARKERS
7.4.3.1 Cell-free mRNA, miRNA, and tumor-educated platelets (TEP) used for early detection
TABLE 45 GLOBAL MARKET FOR OTHER BIOMARKERS, BY REGION, 2018–2025 (USD MILLION)
8 BREAST BIOPSY MARKET, BY GUIDANCE (Page No. - 86)
8.1 INTRODUCTION
TABLE 46 GLOBAL MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
8.2 IMAGE GUIDED BIOPSY
TABLE 47 GLOBAL MARKET FOR IMAGE GUIDED BIOPSY, BY TYPE, 2018–2025 (USD MILLION)
8.2.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY
8.2.1.1 Increasing government-initiated breast screening programs to drive segment growth
TABLE 48 GLOBAL MARKET FOR MAMMOGRPHY-GUIDED STEREOTACTIC BIOPSY, BY REGION, 2018–2025 (USD MILLION)
8.2.2 ULTRASOUND-GUIDED BIOPSY
8.2.2.1 Advantages of technique resulting in rising adoption
TABLE 49 GLOBAL MARKET FOR ULTRASOUND-GUIDED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
8.2.3 MRI GUIDED BIOPSY
8.2.3.1 High cost and low specificity affecting segment growth
TABLE 50 GLOBAL MARKET FOR MRI GUIDED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
8.2.4 OTHER GUIDANCE TECHNIQUES
8.2.4.1 Ongoing research and clinical trials creating more opportunities in the market
TABLE 51 GLOBAL MARKET FOR OTHER GUIDANCE TECHNIQUES, BY REGION, 2018–2025 (USD MILLION)
8.3 LIQUID BIOPSY
TABLE 52 GLOBAL MARKET FOR LIQUID BIOPSY, BY TYPE, 2018–2025 (USD MILLION)
8.3.1 PCR-BASED BIOPSY
8.3.1.1 Expected to hold major share of market over forecast period
TABLE 53 GLOBAL MARKET FOR PCR-BASED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
8.3.2 NGS-BASED BIOPSY
8.3.2.1 Technological advancements and advantages expected to drive growth
TABLE 54 NGS-BASED TECHNOLOGIES FOR ONCOLOGY APPLICATIONS
TABLE 55 GLOBAL MARKET FOR NGS-BASED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
8.3.3 MICROARRAY-BASED BIOPSY
8.3.3.1 Ongoing research and promising results expected to drive segment growth
TABLE 56 GLOBAL MARKET FOR MICROARRAY-BASED BIOPSY, BY REGION, 2018–2025 (USD MILLION)
9 BREAST BIOPSY MARKET, BY APPLICATION (Page No. - 96)
9.1 INTRODUCTION
TABLE 57 GLOBAL MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
9.2 EARLY CANCER SCREENING
9.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION DRIVING SEGMENT GROWTH
TABLE 58 GLOBAL MARKET FOR EARLY CANCER SCREENING, BY REGION, 2018–2025 (USD MILLION)
9.3 THERAPY SELECTION
9.3.1 EMERGENCE OF PLASMA-BASED GENOTYPING EXPECTED TO DRIVE GROWTH IN DEVELOPED COUNTRIES
TABLE 59 GLOBAL MARKET FOR THERAPY SELECTION, BY REGION, 2018–2025 (USD MILLION)
9.4 TREATMENT MONITORING
9.4.1 LIQUID BIOPSY GAINING ATTENTION FOR REAL TIME TREATMENT MONITORING
TABLE 60 GLOBAL MARKET FOR TREATMENT MONITORING, BY REGION, 2018–2025 (USD MILLION)
9.5 RECURRENCE MONITORING
9.5.1 UNMET CLINICAL NEEDS CREATING OPPORTUNITIES FOR PLAYERS IN THE MARKET
TABLE 61 GLOBAL MARKET FOR RECURRENCE MONITORING, BY REGION, 2018–2025 (USD MILLION)
10 BREAST BIOPSY MARKET, BY REGION (Page No. - 102)
10.1 INTRODUCTION
TABLE 62 GLOBAL MARKET, BY REGION, 2018–2025 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: BREAST BIOPSY MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 65 NORTH AMERICA: MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 66 NORTH AMERICA: NEEDLE BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 67 NORTH AMERICA: OPEN SURGICAL BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 68 NORTH AMERICA: LIQUID BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 71 NORTH AMERICA: IMAGE GUIDED BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 72 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
10.2.1 US
10.2.1.1 Dominates the North American market
TABLE 73 MEDICARE REIMBURSEMENT FOR BREAST BIOPSY PROCEDURES (2020)
TABLE 74 US: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Surge in breast cancer incidence and favorable government guidelines to support market growth
TABLE 75 CANADA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3 EUROPE
TABLE 76 EUROPE: BREAST BIOPSY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 77 EUROPE: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 78 EUROPE: MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 79 EUROPE: NEEDLE BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 80 EUROPE: OPEN SURGICAL BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 81 EUROPE: LIQUID BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 EUROPE: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 83 EUROPE: MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 84 EUROPE: IMAGE GUIDED BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 85 EUROPE: LIQUID BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Favorable reimbursement scenario to fuel adoption of biopsy tests
TABLE 86 GERMANY: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3.2 UK
10.3.2.1 Public and private initiatives to increase awareness about breast cancer
TABLE 87 UK: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Growing geriatric population and rising awareness to support market growth
TABLE 88 FRANCE: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Evolving regulatory scenario for breast biopsy and rising incidence of cancer driving market
TABLE 89 ITALY: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growing geriatric population major reason for market growth
TABLE 90 SPAIN: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 91 ROE: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: BREAST BIOPSY MARKET SNAPSHOT
TABLE 92 ASIA PACIFIC: MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 93 ASIA PACIFIC: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 94 ASIA PACIFIC: MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 95 ASIA PACIFIC: NEEDLE BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 96 ASIA PACIFIC: OPEN SURGICAL BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 97 ASIA PACIFIC: LIQUID BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 98 ASIA PACIFIC: BREAST-BIOPSY MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 99 ASIA PACIFIC: BREAST-BIOPSY MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 100 ASIA PACIFIC: IMAGE GUIDED BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
10.4.1 CHINA
10.4.1.1 Increasing patient pool and government healthcare initiatives fueling market growth
TABLE 102 CHINA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Universal healthcare reimbursement scenario and rising breast cancer cases
TABLE 103 JAPAN: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Government initiatives to improve female health to drive market growth
TABLE 104 INDIA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Rising research investments and awareness campaigns supporting market growth
TABLE 105 AUSTRALIA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising R&D and promising clinical trials expected to positively impact market growth
TABLE 106 SOUTH KOREA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.4.6 REST OF APAC
TABLE 107 ROAPAC: BREAST BIOPSY MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.5 LATIN AMERICA
TABLE 108 LATIN AMERICA: MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 109 LATIN AMERICA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 110 LATIN AMERICA: MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 111 LATIN AMERICA: NEEDLE BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 112 LATIN AMERICA: OPEN SURGICAL BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 113 LATIN AMERICA: LIQUID BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 114 LATIN AMERICA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 115 LATIN AMERICA: MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 116 LATIN AMERICA: IMAGE GUIDED BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 117 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Key market due to increased screening programs
TABLE 118 BRAZIL: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Increasing awareness programs fueling market growth
TABLE 119 MEXICO: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.5.3 REST OF LA
TABLE 120 ROLA: MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
10.5.4 MIDDLE EAST & AFRICA
10.5.4.1 Improving healthcare infrastructure and increasing public–private investments to drive market growth
TABLE 121 MEA: BREAST BIOPSY MARKET, BY PRODUCTS, 2018–2025 (USD MILLION)
TABLE 122 MEA: MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 123 MEA: NEEDLE BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 124 MEA: OPEN SURGICAL BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 125 MEA: LIQUID BREAST-BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 126 MEA: MARKET, BY APPLICATION, 2018–2025 (USD MILLION)
TABLE 127 MEA: MARKET, BY GUIDANCE, 2018–2025 (USD MILLION)
TABLE 128 MEA: IMAGE GUIDED BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 129 MEA: LIQUID BIOPSY MARKET, BY TYPE, 2018–2025 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 142)
11.1 OVERVIEW
FIGURE 23 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2017 TO 2020
11.2 MARKET SHARE ANALYSIS
FIGURE 24 GLOBAL NEEDLE BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2019
FIGURE 25 GLOBAL LIQUID BREAST BIOPSY MARKET SHARE, BY KEY PLAYER, 2019
11.3 KEY MARKET DEVELOPMENTS
11.3.1 PRODUCT LAUNCHES AND APPROVALS
11.3.2 ACQUISITIONS
11.3.3 PARTNERSHIPS AND AGREEMENTS
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES (Page No. - 147)
(Business Overview, Products Offered, Recent Developments, MNM view)*
12.1 COMPANY EVALUATION MATRIX AND METHODOLOGY
12.1.1 COMPETITIVE LEADERSHIP MAPPING: MAJOR MARKET PLAYERS (2019)
12.1.2 VISIONARY LEADERS
12.1.3 INNOVATORS
12.1.4 DYNAMIC DIFFERENTIATORS
12.1.5 EMERGING COMPANIES
12.2 COMPANY EVALUATION MATRIX, 2019
FIGURE 26 BREAST BIOPSY MARKET (GLOBAL) COMEPITIVE LEADERSHIP MAPPING, 2019
12.3 COMPANY PROFILES
12.3.1 HOLOGIC, INC.
FIGURE 27 HOLOGIC, INC.: COMPANY SNAPSHOT
12.3.2 DANAHER CORPORATION
FIGURE 28 DANAHER CORPORATION: COMPANY SNAPSHOT
12.3.3 BECTON, DICKINSON AND COMPANY
FIGURE 29 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
12.3.4 ARGON MEDICAL
12.3.5 IZI MEDICAL PRODUCTS
12.3.6 MERIT MEDICAL SYSTEMS
FIGURE 30 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT
12.3.7 MENARINI SILICON BIOSYSTEMS SPA
12.3.8 SCION MEDICAL TECHNOLOGIES, LLC
FIGURE 31 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT
12.3.9 MEDTRONIC
FIGURE 32 MEDTRONIC: COMPANY SNAPSHOT
12.3.10 STERYLAB S.R.L.
12.3.11 BIOCEPT, INC
FIGURE 33 BIOCEPT INC.: COMPANY SNAPSHOT
12.3.12 BIO-RAD LABORATORIES, INC.
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
12.3.13 F. HOFFMANN-LA ROCHE LTD
FIGURE 35 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
12.3.14 QIAGEN
FIGURE 36 QIAGEN: COMPANY SNAPSHOT
12.3.15 EXACT SCIENCES CORPORATION
FIGURE 37 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT
12.3.16 OTHER COMPANIES
12.3.16.1 Thermo Fisher Scientific
12.3.16.2 Cardiff Oncology, Inc.
12.3.16.3 Myriad Genetics, Inc.
12.3.16.4 Illumina, INC
12.3.16.5 Fluxion Biosciences, Inc.
*Details on Business overview, Products offered, Recent Developments, SWOT Analysis, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 177)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the breast biopsy market. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring knowledge about the breast biopsy market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as personnel from hospitals, breast care clinics, cancer research laboratories, Ambulatory Surgery Centers, and radiology centers) and supply-side (such as presidents, CEOs, vice presidents, directors, general managers, heads of business units, and senior managers). Approximately 60% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 40%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the pimary respondents is provided below:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
All major product manufacturers offering various breast biopsy products were identified at the global/regional level. Revenue mapping was done for the major players (who contribute at least 90-95% of the overall market share at the global level) and was extrapolated to arrive at the global market value of each product segment. The market value of breast biopsy products was also split into various segments and subsegments at the region and country-level based on:
- Product mapping of various manufacturers for each type of breast biopsy product at the regional and country-level
- Relative adoption pattern of each breast biopsy product among key end-users at the regional and country-level
- Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country-level
- Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level.
To know about the assumptions considered for the study, Request for Free Sample Report
Data Triangulation
After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the breast biopsy industry.
Report Objectives
- To define, describe, and forecast the breast biopsy market by product, type, application, guidance, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micro markets with respect to their growth trends, prospects, and contributions to the total market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the revenue of market segments with respect to five regions, namely, North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and LoLA), and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches and product enhancements; agreements, partnerships, and collaborations; acquisitions; and R&D developments in the breast biopsy market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the present global breast biopsy market report:
Product Analysis
- Product matrix, which gives a detailed comparison of the product portfolios of the top five companies
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Geographic Analysis
- Further breakdown of the Rest of Europe breast biopsy market into Belgium, Austria, the Czech Republic, Denmark, Greece, Poland, and Russia, among other
- Further breakdown of the Rest of Asia Pacific breast biopsy market into wan, New Zealand, Vietnam, the Philippines, Singapore, Malaysia, Thailand, and Indonesia among other
- Further breakdown of the Latin American breast biopsy market into Argentina, Chile, Peru, and Colombia, among other
Growth opportunities and latent adjacency in Breast Biopsy Market